Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial

NCT04808531 is registered in ClinicalTrials.gov with Medlab Clinical as lead sponsor.

NCT NCT04808531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04808531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial
Lead sponsor
Medlab Clinical
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2023
Completion date
June 30, 2024
Enrollment
360 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer related pain